Holen Sie sich die Stockscreener-App
33.33
1.13%
-0.38
Handel nachbörslich:
33.33
Schlusskurs vom Vortag:
$33.71
Offen:
$33.71
24-Stunden-Volumen:
402.65K
Relative Volume:
0.57
Marktkapitalisierung:
$1.97B
Einnahmen:
$184.42M
Nettoeinkommen (Verlust:
$-6.89M
KGV:
-224.44
EPS:
-0.1485
Netto-Cashflow:
$44.92M
1W Leistung:
-6.40%
1M Leistung:
+1.46%
6M Leistung:
+5.37%
1J Leistung:
+251.95%
1-Tages-Spanne:
$33.15
$34.31
1-Wochen-Bereich:
$33.15
$37.00
52-Wochen-Spanne:
$8.30
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
33.33 | 1.99B | 184.42M | -6.89M | 44.92M | -0.1485 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-05 | Eingeleitet | Guggenheim | Buy |
| 2026-01-05 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2025-07-18 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
(STOK) Volatility Zones as Tactical Triggers - Stock Traders Daily
Stoke Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
STOK Should I Buy - Intellectia AI
[ARS] Stoke Therapeutics, Inc. SEC Filing - Stock Titan
Executive pay, board elections and new auditor at Stoke Therapeutics (NASDAQ: STOK) - Stock Titan
De-Risked Phase 3 Design and Durable Efficacy Support Buy Rating on Stoke Therapeutics’ Zorevunersen - TipRanks
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)April 16, 2026 - BioSpace
Stoke Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $40 - Moomoo
STOK: Zorevunersen shows sustained efficacy and cognitive gains, with phase III readout expected mid-2027 - TradingView
Price-Driven Insight from (STOK) for Rule-Based Strategy - Stock Traders Daily
Baillie Gifford & Co. Purchases New Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Fed Meeting: Is Stoke Therapeutics Inc a strong candidate for buy and hold2026 Bull vs Bear & Weekly Market Pulse Alerts - baoquankhu1.vn
Treasury Yields: Is Stoke Therapeutics Inc a cyclical or defensive stock2026 Year in Review & Verified Momentum Stock Ideas - baoquankhu1.vn
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - BioSpace
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress - NTB Kommunikasjon
Wolfe Research Initiates Coverage on Stoke Therapeutics (STOK) w - GuruFocus
Stoke Therapeutics Appoints Clare Kahn, Ph.D. to Board and Advances Zorevunersen for Dravet Syndrome Treatment - Minichart
Stoke Therapeutics Appoints Clare Kahn to Board - citybiz
Stoke Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Stoke Therapeutics (STOK) director receives 30,782-share stock option grant - Stock Titan
Stoke Therapeutics (STOK) director Kahn Clare submits initial Form 3 insider report - Stock Titan
Stoke Therapeutics appoints Clare Kahn to board of directors By Investing.com - Investing.com India
Stoke Therapeutics Adds Veteran Leader to Board, R&D Oversight - TipRanks
Stoke Therapeutics appoints Clare Kahn to board of directors - Investing.com
Clare Kahn joins Stoke Therapeutics (Nasdaq: STOK) board, receives option grant - Stock Titan
Stoke Therapeutics, Inc. Appoints Clare Kahn as Directors and to Serve on Nominating and Corporate Governance Committee and as Chairperson of the Research and Development Committee of the Board, Effective April 3, 2026 - marketscreener.com
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors - Yahoo Finance
Trading Recap: Can Stoke Therapeutics Inc grow without external fundingQuarterly Market Summary & Technical Entry and Exit Tips - baoquankhu1.vn
Stoke Therapeutics Auditor Switch Puts Biotech Governance In Focus - Yahoo Finance
Growth Value: What is the earnings history of Stoke Therapeutics Inc2026 Major Catalysts & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti - GuruFocus
Stoke Therapeutics (STOK) CMO sells 1,838 shares in planned open-market trade - Stock Titan
(STOK) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Stoke Therapeutics (STOK) Price Target Increased by 16.51% to 28.79 - MSN
Insider sells shares under 10b5-1 — STOK (NASDAQ: STOK) discloses trades - Stock Titan
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
STOK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Stoke Therapeutics (STOK) price target increased by 12.11% to 43.96 - MSN
Stoke Therapeutics Hits Day High with 7.98% Surge in Strong Intraday Performance - Markets Mojo
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares - AOL.com
Stoke Therapeutics, Inc. Files 8-K Announcing Change in Certifying Accountant – March 2026 - minichart.com.sg
Stoke Therapeutics (NASDAQ: STOK) replaces KPMG with EY as auditor - stocktitan.net
Vanguard reports zero Stoke Therapeutics holdings (STOK) - stocktitan.net
Big Money Moves: What hedge funds are buying Stoke Therapeutics Inc2026 Update & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Stoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Whale Trades: What is the earnings history of Stoke Therapeutics IncAnalyst Upgrade & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Assenagon Asset Management S.A. Boosts Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Gains Recap: How does Stoke Therapeutics Inc score in quality rankings2026 Historical Comparison & Expert Curated Trade Setups - baoquankhu1.vn
Allan Jonathan, Stoke Therapeutics general counsel, sells $313k in STOK stock - Investing.com Canada
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):